drug · protein
ZEPBOUND
Marketedupdated 3mo ago/ tur-ZEP-ə-tyde /
by $LLY ELI LILLY & Co🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $4.9B
community read0 votes
🐶 often sniffed alongside
top 6Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.
indications
investigational
Obesity
targets
Glucagon-like peptide 1 receptorGastric inhibitory polypeptide receptor
all catalysts(24)
approval · 24
May 13, 2022
approval
$LLY1244.40-2.81%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jul 28, 2023
approval
$LLY1244.40-2.81%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jul 28, 2023
approval
$LLY1244.40-2.81%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 8, 2023
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Mar 28, 2024
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1244.40-2.81%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1244.40-2.81%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1244.40-2.81%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Dec 20, 2024
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Feb 7, 2025
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
May 28, 2025
approval
$LLY1244.40-2.81%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Sep 25, 2025
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Sep 25, 2025
approval
$LLY1244.40-2.81%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Dec 19, 2025
approval
$LLY1244.40-2.81%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 7, 2026
approval
$LLY1244.40-2.81%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 7, 2026
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 20, 2026
approval
$LLY1244.40-2.81%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 20, 2026
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Feb 25, 2026
approval
$LLY1244.40-2.81%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Trials studying ZEPBOUND
- phase2A Study to Evaluate ALN-2232 in Participants With Obesity
- phase3A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- phase4AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
- phase3A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- phase3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
- phase3Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- phase2A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
- phase3Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 8, 2026
79 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (216)
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4228)US 12343382
- Jul 22, 2039method-of-use (U-4227)US 12343382
- Jul 22, 2039method-of-use (U-4231)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4229)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4401)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4309)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4309)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-4377)US 12453755
- Jun 14, 2039method-of-use (U-4385)US 12453755
- Jun 14, 2039method-of-use (U-4386)US 12453755
- Jun 14, 2039method-of-use (U-4378)US 12453755
- Jun 14, 2039method-of-use (U-4386)US 12453755
- Jun 14, 2039method-of-use (U-4381)US 12453755
- Jun 14, 2039method-of-use (U-4380)US 12453755
- Jun 14, 2039method-of-use (U-4377)US 12453755
- Jun 14, 2039method-of-use (U-4378)US 12453755
- Jun 14, 2039method-of-use (U-4386)US 12453755
- Jun 14, 2039method-of-use (U-4376)US 12453755
- Jun 14, 2039method-of-use (U-4383)US 12453755
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
FDA exclusivities (62)
- Dec 19, 2028NPPNew Product (3y)2.3y
- Dec 19, 2028NPPNew Product (3y)2.3y
- Dec 19, 2028NPPNew Product (3y)2.3y
- Dec 19, 2028NPPNew Product (3y)2.3y
- Dec 19, 2028NPPNew Product (3y)2.3y
- Dec 19, 2028NPPNew Product (3y)2.3y
- Dec 19, 2028NPPNew Product (3y)2.3y
- Dec 19, 2028NPPNew Product (3y)2.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Dec 20, 2027I-958Indication (3y)1.3y
- Oct 18, 2027M-82Method (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.2y
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- May 13, 2027NCENew Chemical Entity (5y)265d
- Nov 8, 2026NPNP79d
- Nov 8, 2026NPNP79d
- Nov 8, 2026NPNP79d
- Nov 8, 2026NPNP79d
- Nov 8, 2026NPNP79d
- Nov 8, 2026NPNP79d
News(10)
- Roche pours $750M into Oregon manufacturing plant as obesity push expandsAfter committing $2 billion to a new North Carolina facility to boost capacity for its next-gen obesity candidates, Roche's Genentech is putting down more cash to expand a device fill-finish site i…biospace · 7h ago
- Enveda’s exercise-simulating obesity tablet clears early clinical testTouting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.biospace · 1d ago
- Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.biospace · 1d ago
- Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemiaWith a Phase 3 trial showing a reduction of serious and severe hypoglycemic episodes in patients who have undergone weight loss surgery, Amylyx Pharmaceuticals plans to file for approval this year.…biospace · 2d ago
- Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 winAmylyx Pharmaceuticals’ $35 million bet on the GLP-1 receptor antagonist avexitide appears to have paid off, with the molecule cutting the number of dangerous blood sugar crashes by more than half…fiercebiotech · 3d ago
- STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and moreSeven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 eachstat · 7d ago
- After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.fiercebiotech · 9d ago
- Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugsMedicare’s new weight loss drug program “risks creating barriers at precisely the moment when confidence in broader GLP‑1 coverage is most needed,” writes Jeffrey Millstein.stat · 9d ago
- Lilly, FDA retatrutide biologic dispute comes to a head as submission nearsA legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicin…biospace · 15d ago
- Lilly climbs, Novo falls as obesity drug battle intensifiesA research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.biopharma_dive · 15d ago
Data sources
last refreshed 42m ago
Found something off?
comments(0)
5-min edit window · permanent after that